Drug intelligence / Profile preview

limosilactobacillus reuteri lr99

Development stage: Unknown
Lead developer: Beijing Huayuan Academy of Biotechnology
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Limosilactobacillus reuteri LR99 is a specific probiotic bacterial strain being investigated for its potential therapeutic effects in children with autism spectrum disorder (ASD). As a live biotherapeutic product, it is hypothesized to modulate the gut-brain axis, potentially improving core ASD symptoms, social functioning, and gastrointestinal issues by altering the gut microbiota composition. The strain is currently being evaluated in clinical trials by the Peking University Sixth Hospital in combination with behavioral interventions for children aged 2 to 6 years.

Other names: Lactobacillus reuteri LR99

Beyond the preview

Go deeper on limosilactobacillus reuteri lr99.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on limosilactobacillus reuteri lr99.

Explore the full profile